ACLX (Arcellx, Inc.) Stock Financials & Earnings | Market Cap Arena

ACLX (Arcellx, Inc.) Stock Financials & Earnings | Market Cap Arena

ACLXArcellx, Inc.

Mkt Cap$7B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$22M

Net Income (TTM)-$229M

EPS (TTM)-$4.06

Free Cash Flow (TTM)-$213M

Gross Margin-64.8%

Op. Margin-1135.6%

Net Margin-1027.3%

FCF Margin-953.9%

P/S Ratio (TTM)300.2x

P/E Ratio (TTM)—

YoY Rev Growth-79.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$18M	$17M	-$30M
Q2 23	$14M	$14M	-$30M
Q3 23	$15M	$15M	-$45M
Q4 23	$63M	$62M	$15M
Q1 24	$39M	$38M	-$16M
Q2 24	$27M	$26M	-$35M
Q3 24	$26M	$26M	-$34M
Q4 24	$15M	$15M	-$53M
Q1 25	$8M	$8M	-$69M
Q2 25	$8M	$8M	-$59M
Q3 25	$5M	-$30M	-$62M
Q4 25	$2M	$13K	-$64M

Valuation

Quarter	P/S	P/E
Q1 23	373.5x	—
Q2 23	207.7x	—
Q3 23	141.8x	—
Q4 23	60.6x	—
Q1 24	50.8x	—
Q2 24	46.2x	—
Q3 24	42.9x	—
Q4 24	62.0x	—
Q1 25	87.1x	—
Q2 25	117.4x	—
Q3 25	186.4x	—
Q4 25	300.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$182M	$181M
Q2 23	-$23M	-$30M
Q3 23	-$10M	-$18M
Q4 23	$58M	$53M
Q1 24	-$32M	-$38M
Q2 24	-$36M	-$39M
Q3 24	$31M	$28M
Q4 24	-$46M	-$48M
Q1 25	-$63M	-$64M
Q2 25	-$40M	-$40M
Q3 25	-$49M	-$50M
Q4 25	-$58M	-$59M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$980K
Q2 23	$7M
Q3 23	$8M
Q4 23	$5M
Q1 24	$6M
Q2 24	$3M
Q3 24	$2M
Q4 24	$1M
Q1 25	$780K
Q2 25	$487K
Q3 25	$296K
Q4 25	$764K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+85.4%
Q2 23	—	+40.2%
Q3 23	—	-36.3%
Q4 23	—	+20.4%
Q1 24	+119.2%	+13.8%
Q2 24	+91.5%	+42.2%
Q3 24	+74.0%	-0.3%
Q4 24	-75.8%	+42.1%
Q1 25	-79.3%	+39.9%
Q2 25	-72.4%	+6.3%
Q3 25	-81.0%	+11.9%
Q4 25	-89.2%	-4.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$10M	56.7%
Q2 23	$0	0.0%
Q3 23	$11M	71.0%
Q4 23	$11M	16.8%
Q1 24	$15M	37.8%
Q2 24	$15M	55.3%
Q3 24	$15M	58.9%
Q4 24	$16M	103.3%
Q1 25	$24M	293.0%
Q2 25	$18M	239.3%
Q3 25	$18M	362.2%
Q4 25	$18M	1092.6%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$33M	—	$15M
Q2 23	$28M	—	$15M
Q3 23	$44M	$16M	—
Q4 23	$29M	$19M	—
Q1 24	$32M	$23M	—
Q2 24	$41M	$21M	—
Q3 24	$39M	$20M	—
Q4 24	$45M	$24M	—
Q1 25	$51M	$26M	—
Q2 25	$38M	$29M	—
Q3 25	$35M	$32M	—
Q4 25	$34M	—	$30M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$275M	$259M	$534M
Q2 23	$304M	$203M	$506M
Q3 23	$126M	$314M	$440M
Q4 23	$395M	$307M	$702M
Q1 24	$155M	$419M	$574M
Q2 24	$100M	$417M	$517M
Q3 24	$162M	$412M	$574M
Q4 24	$106M	$482M	$587M
Q1 25	$81M	$462M	$543M
Q2 25	$62M	$391M	$453M
Q3 25	$79M	$382M	$461M
Q4 25	$80M	$370M	$450M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	47M	+6.0%
Q2 23	48M	+2.9%
Q3 23	48M	+0.7%
Q4 23	52M	+7.9%
Q1 24	53M	+0.9%
Q2 24	54M	+1.4%
Q3 24	54M	+0.6%
Q4 24	54M	-0.2%
Q1 25	55M	+2.9%
Q2 25	56M	+1.7%
Q3 25	57M	+0.7%
Q4 25	56M	-0.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	$0	78
FY 22	$0	98
FY 23	$849K	130
FY 24	$662K	163
FY 25	$223	100K